Thurston Springer Miller Herd & Titak Inc. Has $2.11 Million Stake in Boston Scientific Co. (NYSE:BSX)

Thurston Springer Miller Herd & Titak Inc. boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 274.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,895 shares of the medical equipment provider's stock after buying an additional 15,310 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.'s holdings in Boston Scientific were worth $2,108,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $33,074,000. DAVENPORT & Co LLC lifted its stake in shares of Boston Scientific by 5.0% during the 4th quarter. DAVENPORT & Co LLC now owns 11,829 shares of the medical equipment provider's stock worth $1,057,000 after buying an additional 561 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Boston Scientific by 25.5% during the 4th quarter. Spire Wealth Management now owns 9,174 shares of the medical equipment provider's stock worth $819,000 after buying an additional 1,865 shares during the period. Finally, U.S. Capital Wealth Advisors LLC grew its stake in Boston Scientific by 28.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 3,723 shares of the medical equipment provider's stock valued at $333,000 after buying an additional 829 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 411,970 shares of company stock worth $42,406,693. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.79 during midday trading on Friday, hitting $102.04. 9,114,389 shares of the company traded hands, compared to its average volume of 6,465,793. The firm's fifty day moving average price is $100.47 and its 200-day moving average price is $98.29. The stock has a market cap of $150.96 billion, a price-to-earnings ratio of 81.63, a PEG ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The company's revenue was up 20.9% on a year-over-year basis. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Barclays increased their price objective on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Truist Financial raised their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Finally, Needham & Company LLC restated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Twenty-one equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $116.00.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.